Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia

Journal of Lipid Research

Volumn 53, Issue 4, 2012, Pages 767-775

  Orsoni, Alexina ^a,b   Villard, Elise F ^a,b   Bruckert, Eric ^a,b   Robillard, Paul ^a,b   Carrie, Alain ^a,b   Bonnefont Rousselot, Dominique ^a,c   Chapman, M John ^a,b   Dallinga Thie, Geesje M ^d   Le Goff, Wilfried ^a,b   Guerin, Maryse ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cellular cholesterol efflux; Cholesteryl ester transfer protein; High density lipoprotein; High density lipoprotein cholesteryl ester uptake; Low density lipoprotein

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ATORVASTATIN; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ANIMAL CELL; APHERESIS; ARTICLE; BLOOD SAMPLING; CELL TRANSPORT; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE CHOLESTEROL TRANSPORT;

ADULT; ANIMALS; APOLIPOPROTEINS B; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD COMPONENT REMOVAL; CHO CELLS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CRICETINAE; ESTERIFICATION; FEMALE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; MACROPHAGES; MALE; MICE; MIDDLE AGED; SCAVENGER RECEPTORS, CLASS B; YOUNG ADULT;

EID: 84859378961     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M024141     Document Type: Article

References (39)

1. Marduel, M., A. Carrie, A. Sassolas, M. Devillers, V. Carreau, M. Di Filippo, D. Erlich, M. Abifadel, A. Marques-Pinheiro, A. Munnich, et al. 2010. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum. Mutat. 31: E1811-E1824.
2. Jansen, A. C., S. van Wissen, J. C. Defesche, and J. J. Kastelein. 2002. Phenotypic variability in familial hypercholesterolaemia: an update. Curr. Opin. Lipidol. 13: 165-171. (Pubitemid 34280768)
3. Jansen, A. C., E. S. van Aalst-Cohen, M. W. Tanck, M. D. Trip, P. J. Lansberg, A. H. Liem, H. W. van Lennep, E. J. Sijbrands, and J. J. Kastelein. 2004. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 256: 482-490. (Pubitemid 39577582)
4. van Aalst-Cohen, E. S., A. C. Jansen, S. M. Boekholdt, M. W. Tanck, M. R. Fontecha, S. Cheng, J. Li, J. C. Defesche, J. A. Kuivenhoven, and J. J. Kastelein. 2005. Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. Eur. J. Hum. Genet. 13: 1137-1142. (Pubitemid 41486224)
5. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, Jr., S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15.
6. Kontush, A., and M. J. Chapman. 2006. Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med. 3: 144-153.
7. Bellanger, N., A. Orsoni, Z. Julia, N. Fournier, E. Frisdal, E. Duchene, E. Bruckert, A. Carrie, D. Bonnefont-Rousselot, J. Pirault, et al. 2011. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 31: 1675-1681.
8. Marais, A. D. 2004. Familial hypercholesterolaemia. Clin. Biochem. Rev. 25: 49-68.
9. Pisciotta, L., T. Fasano, A. Bellocchio, L. Bocchi, R. Sallo, R. Fresa, I. Colangeli, A. Cantafora, S. Calandra, and S. Bertolini. 2007. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis. 194: e116-e122. (Pubitemid 47513100)
10. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., and N. J. Stone. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 110: 227-239. (Pubitemid 38924592)
11. Thompson, G. R. 2003. LDL apheresis. Atherosclerosis. 167: 1-13. (Pubitemid 36258395)
12. Thompson, G. R. 2008. Recommendations for the use of LDL apheresis. Atherosclerosis. 198: 247-255.
13. Parhofer, K. G., H. C. Geiss, and P. Schwandt. 2000. Efficacy of different low-density lipoprotein apheresis methods. Ther. Apher. 4: 382-385.
14. Franceschini, G., P. Apebe, L. Calabresi, G. Busnach, L. Minetti, V. Vaccarino, and C. R. Sirtori. 1988. Alterations in the HDL system after rapid plasma cholesterol reduction by LDL-apheresis. Metabolism. 37: 752-757.
15. Guerin, M., T. S. Lassel, W. Le Goff, M. Farnier, and M. J. Chapman. 2000. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20: 189-197. (Pubitemid 30048363)
16. Miyazaki, O., J. Kobayashi, I. Fukamachi, T. Miida, H. Bujo, and Y. Saito. 2000. A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels. J. Lipid Res. 41: 2083-2088. (Pubitemid 32039004)
17. Chapman, M. J., S. Goldstein, D. Lagrange, and P. M. Laplaud. 1981. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 22: 339-358. (Pubitemid 11125137)
18. Guérin, M., P. J. Dolphin, and M. J. Chapman. 1994. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler. Thromb. 14: 199-206.
19. Niemeijer-Kanters, S. D., G. M. Dallinga-Thie, F. C. de Ruijter-Heijstek, A. Algra, D. W. Erkelens, J. D. Banga, and H. Jansen. 2001. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. Atherosclerosis. 156: 209-216. (Pubitemid 32429614)
20. Albers, J. J., C. H. Chen, and A. G. Lacko. 1986. Isolation, characterization, and assay of lecithin-cholesterol acyltransferase. Methods Enzymol. 129: 763-783. (Pubitemid 16055980)
21. Catalano, G., E. Duchene, Z. Julia, W. Le Goff, E. Bruckert, M. J. Chapman, and M. Guerin. 2008. Cellular SR-BI and ABCA1- mediated cholesterol efflux are gender-specific in healthy subjects. J. Lipid Res. 49: 635-643.
22. Catalano, G., Z. Julia, E. Frisdal, B. Vedie, N. Fournier, W. Le Goff, M. J. Chapman, and M. Guerin. 2009. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler. Thromb. Vasc. Biol. 29: 268-275.
23. Gelissen, I. C., M. Harris, K. A. Rye, C. Quinn, A. J. Brown, M. Kockx, S. Cartland, M. Packianathan, L. Kritharides, and W. Jessup. 2006. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol. 26: 534-540.
24. Larrede, S., C. M. Quinn, W. Jessup, E. Frisdal, M. Olivier, V. Hsieh, M. J. Kim, M. Van Eck, P. Couvert, A. Carrie, et al. 2009. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler. Thromb. Vasc. Biol. 29: 1930-1936.
25. Le Goff, W., M. Settle, D. J. Greene, R. E. Morton, and J. D. Smith. 2006. Reevaluation of the role of the multidrug-resistant P-glycoprotein in cellular cholesterol homeostasis. J. Lipid Res. 47: 51-58. (Pubitemid 43107448)
26. Marcel, Y. L., R. McPherson, M. Hogue, H. Czarnecka, Z. Zawadzki, P. K. Weech, M. E. Whitlock, A. R. Tall, and R. W. Milne. 1990. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J. Clin. Invest. 85: 10-17. (Pubitemid 20030284)
27. McPherson, R., C. J. Mann, A. R. Tall, M. Hogue, L. Martin, R. W. Milne, and Y. L. Marcel. 1991. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler. Thromb. 11: 797-804.
28. Le, N. A., W. Innis-Whitehouse, X. Li, R. Bakker-Arkema, D. Black, and W. V. Brown. 2000. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism. 49: 167-177. (Pubitemid 30090879)
29. van Venrooij, F. V., R. P. Stolk, J. D. Banga, T. P. Sijmonsma, A. van Tol, D. W. Erkelens, and G. M. Dallinga-Thie. 2003. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care. 26: 1216-1223.
30. Hajer, G. R., G. M. Dallinga-Thie, L. C. van Vark-van der Zee, J. K. Olijhoek, and F. L. Visseren. 2008. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. Clin. Endocrinol. (Oxf.). 69: 870-877.
31. Morton, R. E. 1985. Binding of plasma-derived lipid transfer protein to lipoprotein substrates. The role of binding in the lipid transfer process. J. Biol. Chem. 260: 12593-12599. (Pubitemid 16233463)
32. Nishida, H. I., H. Arai, and T. Nishida. 1993. Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. J. Biol. Chem. 268: 16352-16360. (Pubitemid 23229938)
33. Le Goff, W., M. Guerin, and M. J. Chapman. 2004. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol. Ther. 101: 17-38. (Pubitemid 38068523)
34. Oram, J. F., and R. M. Lawn. 2001. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 42: 1173-1179. (Pubitemid 32744239)
35. Williams, D. L., M. A. Connelly, R. E. Temel, S. Swarnakar, M. C. Phillips, M. de la Llera-Moya, and G. H. Rothblat. 1999. Scavenger receptor BI and cholesterol trafficking. Curr. Opin. Lipidol. 10: 329-339. (Pubitemid 29419690)
36. Wang, N., D. Lan, W. Chen, F. Matsuura, and A. R. Tall. 2004. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. USA. 101: 9774-9779. (Pubitemid 38869312)
37. von Eckardstein, A., J. R. Nofer, and G. Assmann. 2001. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21: 13-27. (Pubitemid 32061923)
38. Sviridov, D., and P. Nestel. 2002. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 161: 245-254. (Pubitemid 34219176)
39. Settasatian, N., M. Duong, L. K. Curtiss, C. Ehnholm, M. Jauhiainen, J. Huuskonen, and K. A. Rye. 2001. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J. Biol. Chem. 276: 26898-26905.